• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to: "developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond".

作者信息

Hatanaka Takeshi, Kakizaki Satoru, Hiraoka Atsushi, Toyoda Hidenori, Kumada Takashi

机构信息

Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, 564-1 Kamishindenmachi, Maebashi, 371-0821, Japan.

Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.

出版信息

Hepatol Int. 2023 Oct;17(5):1320-1321. doi: 10.1007/s12072-023-10554-5. Epub 2023 Jun 3.

DOI:10.1007/s12072-023-10554-5
PMID:37269477
Abstract
摘要

相似文献

1
Reply to: "developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond".回复：“为晚期肝细胞癌患者开发真实世界预后模型：CRAFITY、mALF及其他”
Hepatol Int. 2023 Oct;17(5):1320-1321. doi: 10.1007/s12072-023-10554-5. Epub 2023 Jun 3.
2
Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond.为晚期肝细胞癌患者开发真实世界预后模型：CRAFITY、mALF及其他。
Hepatol Int. 2023 Apr;17(2):512-513. doi: 10.1007/s12072-022-10467-9. Epub 2022 Dec 24.
3
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.免疫治疗肝细胞癌患者的预后——CRAFITY 评分的建立和验证。
J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12.
4
Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis.CRAFITY 评分对接受免疫治疗的肝细胞癌的预后意义：系统评价和荟萃分析。
BMC Cancer. 2023 Mar 13;23(1):236. doi: 10.1186/s12885-023-10686-9.
5
Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?CRAFITY 评分是否能更好地预测接受局部免疫治疗的肝细胞癌患者的预后和不良事件？
Hepatol Int. 2023 Oct;17(5):1279-1288. doi: 10.1007/s12072-023-10535-8. Epub 2023 May 2.
6
Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".回复：“CRAFITY评分：酪氨酸激酶抑制剂与免疫疗法联合治疗肝细胞癌患者的一种有前景的预后预测指标”
J Hepatol. 2022 Aug;77(2):576-577. doi: 10.1016/j.jhep.2022.04.030. Epub 2022 May 5.
7
Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy".回复：“CRAFITY评分：接受免疫治疗的肝细胞癌患者预后预测的新指南”。
J Hepatol. 2022 May;76(5):1233-1234. doi: 10.1016/j.jhep.2022.02.002. Epub 2022 Feb 14.
8
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.在接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者中，C 反应蛋白和甲胎蛋白对免疫治疗评分的预后影响：一项多中心回顾性研究。
Hepatol Int. 2022 Oct;16(5):1150-1160. doi: 10.1007/s12072-022-10358-z. Epub 2022 Jun 24.
9
The CRAFITY score: A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations.CRAFITY评分：酪氨酸激酶抑制剂与免疫疗法联合治疗肝细胞癌患者的一种有前景的预后预测指标。
J Hepatol. 2022 Aug;77(2):574-576. doi: 10.1016/j.jhep.2022.03.018. Epub 2022 Mar 26.
10
Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.接受阿替利珠单抗和贝伐单抗治疗的肝细胞癌患者改良白蛋白-胆红素分级和甲胎蛋白评分（mALF评分）的开发与验证
Hepatol Int. 2023 Feb;17(1):86-96. doi: 10.1007/s12072-022-10406-8. Epub 2022 Sep 9.

本文引用的文献

1
Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond.为晚期肝细胞癌患者开发真实世界预后模型：CRAFITY、mALF及其他。
Hepatol Int. 2023 Apr;17(2):512-513. doi: 10.1007/s12072-022-10467-9. Epub 2022 Dec 24.
2
Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study.阿替利珠单抗与贝伐珠单抗治疗乙型和非乙型肝炎病毒感染的肝细胞癌患者的疗效和安全性比较：一项日本多中心观察性研究。
Cancer Med. 2023 Mar;12(5):5293-5303. doi: 10.1002/cam4.5337. Epub 2022 Oct 13.
3
Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.
接受阿替利珠单抗和贝伐单抗治疗的肝细胞癌患者改良白蛋白-胆红素分级和甲胎蛋白评分（mALF评分）的开发与验证
Hepatol Int. 2023 Feb;17(1):86-96. doi: 10.1007/s12072-022-10406-8. Epub 2022 Sep 9.
4
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.在接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者中，C 反应蛋白和甲胎蛋白对免疫治疗评分的预后影响：一项多中心回顾性研究。
Hepatol Int. 2022 Oct;16(5):1150-1160. doi: 10.1007/s12072-022-10358-z. Epub 2022 Jun 24.
5
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.预测肝细胞癌预后的EZ-ALBI评分
Liver Cancer. 2020 Dec;9(6):734-743. doi: 10.1159/000508971. Epub 2020 Oct 23.